Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Completed · Phase 1

Conditions studied: Neoplasms

In brief

To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Key facts

Study ID

NCT02315066

Run by

Pfizer

People needed

174

Starts

2015-04-23

Expected to finish

2020-11-12

Last updated by the study team

2022-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Part A1 only: Patients with histological or cytological diagnosis of HNSCC, HCC, melanoma, or clear cell RCC who progressed on or are intolerant to standard therapy, for which no standard therapy is available or who decline standard therapy.
• Part A2 only: Patients with histological or cytological diagnosis of advanced/metastatic HCC who are treatment naïve and have declined standard of care, or have had at least 1 prior line of systemic therapy. Prior anti PD L1/PD 1 therapy is allowed.
• Part B1 only: Patients with histological or cytological diagnosis of NSCLC, HNSCC, melanoma, urothelial bladder carcinoma (including renal pelvis, ureters, urinary bladder, and urethra), gastric or squamous cell carcinoma of the uterine cervix who progressed on or are intolerant to standard therapy, for which no standard therapy is available, or who decline standard therapy.
• Part B2
• Arm 1 only:
• Ocular melanoma patients with advanced/metastatic disease, or
• Cutaneous/acral melanoma patients with advanced/metastatic disease who have received checkpoint inhibitor (anti PD L1, anti PD 1, or anti CTLA4) based treatment on which disease progressed. [Note: Checkpoint inhibitor may have been part of a combination therapy, as long as the combination did not contain OX40 or 4 1BB agonist.] Any questions on prior treatment may be discussed with the Sponsor.
• Arm 2 only:
• Histological or cytological diagnosis of NSCLC with advanced/metastatic disease. Patients must have previously received prior anti PD L1 or anti PD 1 mAb on which disease progressed. [Note: Previous anti PD L1 or anti PD 1 mAb may have been part of a combination therapy, eg, in combination with chemotherapy, as long as the combination did not contain OX40 or 4 1BB agonist.]
• Performance Status of 0 or 1 - Adequate bone marrow, kidney and liver function

You may not qualify if…

• Brain metastases requiring steroids
• Major surgery, Radiation therapy within 4 weeks of starting study treatment (except: palliative radiotherapy to a limited field is allowed after consultation with sponsor's medical monitor at any time during study participation, including during screening), or systemic anti-cancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas)
• Active and clinically significant bacterial, fungal, or viral infection
• History of active autoimmune disorders
• History of immune-mediated adverse events requiring immunosuppressive therapy or were grade 3 or higher related to prior immune-modulatory therapy
• Prior treatment with an OX40 agonist and 4-1BB agonist (for Part B1/B2)
• Prior anthracycline treatment and at risk of cardiac failure (New York Heart Association Class 2)

Where it is running

• The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate — Los Angeles, California, United States
• Keck Hospital of USC — Los Angeles, California, United States
• LAC+USC Medical Center — Los Angeles, California, United States
• USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Ronald Regan Medical Center — Los Angeles, California, United States
• UCLA Hematology & Oncology Clinic — Los Angeles, California, United States
• Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
• Medical Imaging Center of Southern California, Inc. — Santa Monica, California, United States
• Santa Monica UCLA Hematology & Oncology Clinic — Santa Monica, California, United States
• UConn Health, Pharmacy — Farmington, Connecticut, United States
• UConn Health, Neag Comprehensive Cancer Center — Farmington, Connecticut, United States
• H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
• Massachusetts General Hospital (MGH) — Boston, Massachusetts, United States
• Brigham & Women's Hospital (BWH) — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute (DFCI) — Boston, Massachusetts, United States
• Massachusetts General/Chelsea HealthCare Center — Chelsea, Massachusetts, United States
• Mass General/North Shore Center for Outpatient Care — Danvers, Massachusetts, United States
• Mass General West — Waltham, Massachusetts, United States
• Columbia University Medical Center - Herbert Irving Pavilion — New York, New York, United States
• Methodist Hospital-Pathology — Houston, Texas, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States
• University of Washington Medical Center — Seattle, Washington, United States
• Groupe hospitalier Pitie Salpetriere — Paris, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.